Multimorbidity in Asthma, Allergic Conditions and COPD Increase Disease Severity, Drug Use and Costs: The Finnish Pharmacy Survey

2019 ◽  
Vol 179 (4) ◽  
pp. 273-280 ◽  
Author(s):  
Juha Jantunen ◽  
Tari Haahtela ◽  
Johanna Salimäki ◽  
Miika Linna ◽  
Mika Mäkelä ◽  
...  
1969 ◽  
Vol 15 (6) ◽  
pp. 527-533 ◽  
Author(s):  
J. A. Lewis ◽  
G. C. Papavizas

The flavonoids rutin and quercetin and two of their decomposition products, phloroglucinol and protocatechuic acid, were rapidly degraded in soil. Less than 10% of their phenolic nuclei were detected in soil, and from 27 to 57% of their structural carbons remained in soil after 9 weeks of incubation. Phenolic intermediates were not detected in soils amended with rutin or quercetin. There were no differences in the decomposition of any of the substrates in noninfested soil and in soils infested with F. solani f. sp. phaseoli. In pure culture, two virulent isolates of the pathogen could effectively metabolize a glucose–rhamnose mixture and protocatechuic acid, but only one of the isolates could use phloroglucinol and rutin to any great extent. When incorporated into soil at a rate of 0.1% and 0.3%, rutin, phloroglucinol, protocatechuic acid, and a glucose–rhamnose mixture significantly increased propagule numbers of the pathogen over that of the control. From 1 week, to the termination of the experiment after 9 weeks, more than 80% of the propagules of F. solani f. sp. phaseoli existed in the soils as chlamydospores. Propagule numbers were higher in soils amended with 0.3% substrate than in soils amended with 0.1% substrate, and the numbers 1 week after amendment addition were similar to those obtained 9 weeks after amendment addition. In the first and second crops of beans (planted 3 and 6 weeks after amendment incorporation), protocatechuic acid and phloroglucinol, at a concentration of 0.3%, were very effective in reducing root-rot severity. The other amendments, except quercetin, were effective in suppressing disease to various degrees. The effectiveness of the various amendments depended upon amendment concentration and time of planting. Quercetin, added to soil at either concentration, did not increase inoculum density but did increase disease severity.


2020 ◽  
Vol 14 (12) ◽  
pp. e0008931
Author(s):  
Sudhamshu KC ◽  
Holly Murphy ◽  
Sameer Dixit ◽  
Apurva Rai ◽  
Bickram Pradhan ◽  
...  

Background Despite direct-acting antivirals (DAA), aims to “eradicate” viral hepatitis by 2030 remain unlikely. In Nepal, an expert consortium was established to treat HCV through Nepal earthquakes aftermath offering a model for HCV treatment expansion in a resource-poor setting. Methodology/Principal findings In 2015, we established a network of hepatologists, laboratory experts, and community-based leaders at 6 Opioid Substitution Treatment (OST) sites from 4 cities in Nepal screening 838 patients for a treatment cohort of 600 individuals with HCV infection and past or current drug use. During phase 1, patients were treated with interferon-based regimens (n = 46). During phase 2, 135 patients with optimal predictors (HIV controlled, without cirrhosis, low baseline HCV viral load) were treated with DAA-based regimens. During phase 3, IFN-free DAA treatment was expanded, regardless of HCV disease severity, HIV viremia or drug use. Sustained virologic response (SVR) was assessed at 12 weeks. Median age was 37 years and 95.5% were males. HCV genotype was 3 (53.2%) or 1a (40.7%) and 32% had cirrhosis; 42.5% were HIV-HCV coinfected. The intention-to-treat (ITT) SVR rates in phase 2 and 3 were 97% and 81%, respectively. The overall per-protocol and ITT SVR rates were 97% and 85%, respectively. By multivariable analysis, treatment at the Kathmandu site was protective and substance use, treatment during phase 3 were associated with failure to achieve SVR. Conclusions/Significance Very high SVR rates may be achieved in a difficult-to-treat, low-income population whatever the patient’s profile and disease severity. The excellent treatment outcomes observed in this real-life community study should prompt further HCV treatment initiatives in Nepal.


2001 ◽  
Vol 120 (5) ◽  
pp. A409-A409
Author(s):  
H ELSERAG ◽  
M KUNIK ◽  
P RICHARDSON ◽  
L RABENECK

Ob Gyn News ◽  
2008 ◽  
Vol 43 (2) ◽  
pp. 42
Author(s):  
DOUG BRUNK

Sign in / Sign up

Export Citation Format

Share Document